-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] At present, the entire Chinese medicine industry has ushered in high-quality development with the support of favorable national and local policies, and the new Chinese medicines, formula granules, and Chinese medicine decoction pieces in the sub-sectors are considered by the industry to have great potential.
, the prospect is promising
.
In fact, data shows that in 2020, the overall scale of China's traditional Chinese medicine market (Chinese herbal medicine + Chinese patent medicine + Chinese herbal decoction pieces) has exceeded 800 billion
.
Industry analysts believe that the continuous expansion of the traditional Chinese medicine market is closely related to the marked acceleration of the review of new traditional Chinese medicines and the continuous increase in the number of new drugs on the market in recent years
.
Statistics show that from 2016 to 2020, 13 new traditional Chinese medicines were approved for marketing, and in 2021, a total of 12 new traditional Chinese medicines were launched, setting a new high in the number of approvals in the past five years
.
Entering 2022, the innovation vitality of traditional Chinese medicine is still being released.
In January this year, the 1.
2 class innovative drug icariin soft capsule has been approved by the State Food and Drug Administration for marketing.
This is the first innovative traditional Chinese medicine drug approved for marketing in China in 2022
.
In addition, Yunnan Baiyao announced on March 3 that the company received approval from the State Food and Drug Administration to conduct clinical trials of the company's new class 1 traditional Chinese medicine, Quansanqi Tablets, for chest tightness and heartache caused by blood stasis
.
According to industry forecasts, in the next few years, more than 12 new Chinese medicines will be approved for listing each year
.
It is foreseeable that the market for innovative Chinese medicines will be quite active in the future, and the development space of the Chinese medicine market will continue to expand
.
It is worth mentioning that the development of innovative traditional Chinese medicine drugs is also inseparable from the continuous investment in research and development by the state and pharmaceutical companies
.
In terms of research and development, in recent years, the state has been continuously increasing investment in traditional Chinese medicine research.
In 2020, the financial allocation of traditional Chinese medicine institutions was 98.
19 billion yuan, an increase of 40.
83 billion yuan compared with 57.
36 billion yuan in 2019, an increase of 71.
2%, accounting for the financial allocation of the health department.
7.
4% of 1,333.
15 billion yuan, an increase from 6.
5% in 2019
.
At the same time, the investment of traditional Chinese medicine companies in the research and development of new drugs has also continued to increase
.
For example, according to the third quarterly report of Yiling Pharmaceutical in 2021, in the first three quarters, the company achieved an operating income of 8.
112 billion yuan, a year-on-year increase of 25.
81%; the net profit attributable to shareholders of the listed company was 1.
224 billion yuan, a year-on-year increase of 20.
43%, exceeding that of last year; And in the first three quarters, the R&D expenditure was 538 million yuan, a year-on-year increase of 37.
86%, which was much higher than the revenue growth rate
.
At present, with the continuous increase of research and development investment, the rate of research and development and innovation of traditional Chinese medicine is accelerating, and a number of modern traditional Chinese medicines with significant curative effects have also begun to emerge in the market
.
Data show that in the five years from 2017 to 2021, more than 20 new Chinese medicines have been approved for marketing in China, and the number of approvals has increased from a few to double-digits.
Among them, 12 new Chinese medicines have been approved for the market in 2021.
A new high in the past 5 years
.
In addition, in January 2022, CDE has undertaken a total of 128 new Chinese medicine registration applications with acceptance numbers, and in February CDE has undertaken a total of 92 new drug registration applications with acceptance numbers
.
According to this trend, the research and development of new Chinese medicines will usher in a new development period
.
In the future, with favorable policies, the continuous promotion and application of more innovative TCM drugs with clinical evidence-based medicine value, and the continuous investment of pharmaceutical companies in TCM R&D innovation, the market space is expected to be further opened up.
Industry insiders predict that in 2024 The annual traditional Chinese medicine market will exceed 1 trillion yuan, and the market prospect will become more and more impressive
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, the prospect is promising
.
In fact, data shows that in 2020, the overall scale of China's traditional Chinese medicine market (Chinese herbal medicine + Chinese patent medicine + Chinese herbal decoction pieces) has exceeded 800 billion
.
Industry analysts believe that the continuous expansion of the traditional Chinese medicine market is closely related to the marked acceleration of the review of new traditional Chinese medicines and the continuous increase in the number of new drugs on the market in recent years
.
Statistics show that from 2016 to 2020, 13 new traditional Chinese medicines were approved for marketing, and in 2021, a total of 12 new traditional Chinese medicines were launched, setting a new high in the number of approvals in the past five years
.
Entering 2022, the innovation vitality of traditional Chinese medicine is still being released.
In January this year, the 1.
2 class innovative drug icariin soft capsule has been approved by the State Food and Drug Administration for marketing.
This is the first innovative traditional Chinese medicine drug approved for marketing in China in 2022
.
In addition, Yunnan Baiyao announced on March 3 that the company received approval from the State Food and Drug Administration to conduct clinical trials of the company's new class 1 traditional Chinese medicine, Quansanqi Tablets, for chest tightness and heartache caused by blood stasis
.
According to industry forecasts, in the next few years, more than 12 new Chinese medicines will be approved for listing each year
.
It is foreseeable that the market for innovative Chinese medicines will be quite active in the future, and the development space of the Chinese medicine market will continue to expand
.
It is worth mentioning that the development of innovative traditional Chinese medicine drugs is also inseparable from the continuous investment in research and development by the state and pharmaceutical companies
.
In terms of research and development, in recent years, the state has been continuously increasing investment in traditional Chinese medicine research.
In 2020, the financial allocation of traditional Chinese medicine institutions was 98.
19 billion yuan, an increase of 40.
83 billion yuan compared with 57.
36 billion yuan in 2019, an increase of 71.
2%, accounting for the financial allocation of the health department.
7.
4% of 1,333.
15 billion yuan, an increase from 6.
5% in 2019
.
At the same time, the investment of traditional Chinese medicine companies in the research and development of new drugs has also continued to increase
.
For example, according to the third quarterly report of Yiling Pharmaceutical in 2021, in the first three quarters, the company achieved an operating income of 8.
112 billion yuan, a year-on-year increase of 25.
81%; the net profit attributable to shareholders of the listed company was 1.
224 billion yuan, a year-on-year increase of 20.
43%, exceeding that of last year; And in the first three quarters, the R&D expenditure was 538 million yuan, a year-on-year increase of 37.
86%, which was much higher than the revenue growth rate
.
At present, with the continuous increase of research and development investment, the rate of research and development and innovation of traditional Chinese medicine is accelerating, and a number of modern traditional Chinese medicines with significant curative effects have also begun to emerge in the market
.
Data show that in the five years from 2017 to 2021, more than 20 new Chinese medicines have been approved for marketing in China, and the number of approvals has increased from a few to double-digits.
Among them, 12 new Chinese medicines have been approved for the market in 2021.
A new high in the past 5 years
.
In addition, in January 2022, CDE has undertaken a total of 128 new Chinese medicine registration applications with acceptance numbers, and in February CDE has undertaken a total of 92 new drug registration applications with acceptance numbers
.
According to this trend, the research and development of new Chinese medicines will usher in a new development period
.
In the future, with favorable policies, the continuous promotion and application of more innovative TCM drugs with clinical evidence-based medicine value, and the continuous investment of pharmaceutical companies in TCM R&D innovation, the market space is expected to be further opened up.
Industry insiders predict that in 2024 The annual traditional Chinese medicine market will exceed 1 trillion yuan, and the market prospect will become more and more impressive
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
